LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

MEDIPOST’s CEO Dr Yang Yoonsun Named on the Forbes 2020 List of Asia’s Power Businesswomen

2020/09/16
MEDIPOST

· In recognition of her achievement in founding and growing MEDIPOST as Korea’s largest private cord blood bank and stem cell therapeutics biotech company

MEDIPOST, a leading stem cell biotechnology company, today announced the company’s founder and chief executive officer Yang Yoonsun MD PhD has been named as one of 25 individuals to the Forbes 2020 list of Asia’s Power Businesswomen.

Included in the list released by Forbes Global are 25 outstanding female entrepreneurs who have played a pivotal role in shaping the business environment across Asia by overcoming difficulties and challenges in various industries such as biotechnology, fintech, and entertainment.

Yang, a widely recognized authority in the field of the cord blood and stem cell technology, received MD PhD from Seoul National University School of Medicine and found MEDIPOST in 2000 while working as a medical doctor at the prominent Samsung Medical Center. Yang was in the list in recognition of her untiring efforts in the growth of MEDIPOST as Korea’s largest private cord-blood bank and the country’s leading stem cell biotech company which has successfully developed CARTISTEM®, the world’s first regulatory-approved stem cell therapy product based on allogeneic umbilical cord blood-derived mesenchymal stem cells.

In terms of countries from which the 25 female entrepreneurs came from, India topped the list with four businesswomen, followed by Thailand and China having three persons each. Korea, Australia, Singapore, Japan, Vietnam and Indonesia had two persons each with Malaysia, the Philippines and Hong Kong having one each.

· Forbes ‘2020 Asia’s Power Businesswomen’ List :
https://www.forbes.com/sites/forbesasiateam/2020/09/14/forbes-asias-power-businesswomen-2020-list/#a8f3e8c74d26

· Image Source : forbes.com – 2020 Asia’s Power Businesswomen

VIEW LIST

Related News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14

Latest News

MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
MEDIPOST’s CARTISTEM® Reaches Milestone of treating 30,000 P…
2024/06/24

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Recruits Local Experts to U.S.…2024.12.06
MEDIPOST Completes Administration for Ph…2024.11.22
MEDIPOST Affiliate OmniaBio Hosts Openin…2024.10.21
MEDIPOST Discusses CARTISTEM® Partnershi…2024.10.14
MEDIPOST’s CARTISTEM® Reaches Milestone…2024.06.24

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST